Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARI-HER2 first-in-human dose-escalation trial in HER2-positive advanced breast cancer
2026-527365-30-00Phase 2Authorised
- Sponsor
- IDIBAPS
- Start
- Oct 2026
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ARI-HER2 in breast cancer, sponsored by IDIBAPS. Planned start Oct 2026; status: authorised.
02
Drugs
ARI-HER2
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2026-527365-30-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-527365-30-00.